Contact this trialFirst, we need to learn more about you.
HER2 Inhibitor
ELVN-002 for Non-Small Cell Lung Cancer
Recruiting1 awardPhase 1
Fairfax, Virginia
This trial tests ELVN-002, a new drug, in people with cancers that have an abnormal HER2 gene. It aims to see if the drug is safe and can shrink these tumors, especially in advanced stage solid tumors and non-small cell lung cancer.
Fill-in a few details and create your profileSave answers to your profile & unlock recommendations.
We will keep your details privateWe won't share unless you give us permission. By completing this form you agree to our privacy policy and terms of service
Get in touch with the study teamWe’ll send your responses to the study team and help you to setup your first screening. This is not the start of informed consent. Screening happens between you and the trial.
By clicking start, you agree to our
terms of service